Drug Discovery in Glioblastoma: Current Status and Future Perspectives
Biointerface Research in Applied Chemistry · 2023
Glioblastoma (GB) is the prevalent and malignant type of solid brain tumor, having 10,000 novel incidents recorded each year in the United States. Even though rigorous multi-modal treatment, the overall survival after diagnosis is reported to be less than 15 months, the surgical excision of the tumor, observed by radiotherapy and chemotherapy, is a widely utilized treatment strategy for GB. However, contemporary advances exhibit that exosomes, dendrimers, liposomes, and certain metallic nanoparticles in the form of prodrugs advance the infiltration of the drugs into the blood-brain barriers, consequently contributing to novel chances of combating the GB confrontation with chemotherapeutics. The Food and Drug Administration of the United States (FDA) has accepted numerous medications, and significant initiatives have been adopted for advanced novel chemotherapeutic agents for GB. This overview provides new insights into developing a strong platform likely to be used for exploring certain novel drugs as well as means to treat GB clinically.